• N.D. Gerasimenko Higher State Educational Establishment of Ukraine «Ukrainian Medical Stomatological Academy», Poltava
  • M.S. Rasin Higher State Educational Establishment of Ukraine «Ukrainian Medical Stomatological Academy», Poltava
Keywords: antithrombotic therapy, prevention of vascular events, chronic heart failure


Chronic heart failure is one of the main clinical challenges of modern medicine. The present paper discusses the features of antithrombotic therapy in prevention of cardiovascular events (death, acute myocardial infarction, stroke) in patients with chronic heart failure. It has been specified, which anticoagulants or antiplatelet agents have advantages taking into account the features of the functioning of organs and systems in patients with heart failure. Antithrombotic therapy is indicated for all patients with atrial fibrillation and heart failure. The feasibility of anticoagulant or antithrombotic therapy has not been proven in patients with sinus rhythm, since the risk of bleeding exceeds the antithrombotic effect in patients of this group. The results of controlled trials recommend anticoagulant therapy for patients with heart failure who are at high risk, particularly in atrial fibrillation, with previous thromboembolic episodes, a significant reduction in the left ventricular ejection fraction, intracardiac thrombosis and in patients with aneurysm. There is also no evidence to prescribe antithrombotic therapy for reducing the risk of stroke and thromboembolism in patients with heart failure and sinus rhythm. The choice of antithrombotic therapy should be guided by the CHA2DS2-VASc and HAS-BLAD indices.


Download data is not yet available.


1. Gorbas' ІM, Voronkov LG. Epіdemіologіchnі aspekti hronіchnoї sercevoї nedostatnostі u doroslogo naselennya Ukraїni. Ukraїns'kij kardіologіchnij zhurnal. 2008;4:8-12.
2. Perederij VG, Bezyuk NN. Serdechnaya nedostatochnost': kak uluchshit' kachestvo lecheniya? Zdorov'ya Ukraїni. 2015 Mart 27;74. – URL:
3. Rekomendacii ESC po diagnostike i lecheniyu ostroj i hronicheskoj serdechnoj nedostatochnosti 2016. Evropejskoe Obshchestvo Kardiologov (ESC). Rossijskij kardiologicheskij zhurnal. 2017;1(141):7-81.
4. Barnes G.D., Gu X., Haymart B., Kline-Rogers E., Almany S., Kozlowski J., et al. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI (2) experience // Thromb Res. – 2014. – Vol. 134. – P. 294–299.
5. Cleland J.G., Findlay I., Jafri S., et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trail comparing antithrombotic strategies for patients witch heart failure // Am. Heart. J. – 2004. – Vol. 148 (1). – P. 157–164.
6. Costa F., van Klaveren D., James S., Heg D., Raber L., Feres F., et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials // Lancet. – 2017. – Vol. 389. – P. 1025–1034.
7. Furberg C.D., Psaty B.M., Manolio T.A., Gardin J.M., Smith V.E., Rautaharju P.M. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study) // Am. J. Cardiol. – 1994. – Vol. 74 (3). – P. 236–241.
8. Gladstone D.J., Bui E., Fang J., Laupacis A., Lindsay M.P., Tu J.V. et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated // Stroke. – 2009. – Vol. 40. – P. 235–240.
9. Gómez-Outes A.A., Terleira-Fernández A.I., Calvo-Rojas G., Suárez-Gea M.L., Vargas-Castrillón E. Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta-analysis by geographic region with a focus on European patients // Br J Clin Pharmacol. – 2016. – Vol. 82, Is. 3. – P. 633–644.
10. Gurbel P.A., Tantry U.S. Antiplatelet and Anticoagulant Agents in Heart FailureCurrent Status and Future Perspectives // JCHF. – 2014. – 2 (1). – С. 1–14.
11. Halvorsen S., Storey R.F., Rocca B., Sibbing D., Ten Berg J., Grove E.L., et al. European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. – Eur Heart J. – 2017. – Vol. 38 (19). – P. 1455–1462.
12. Hansen M.L., Sorensen R., Clausen M.T., Fog-Petersen M.L., Raunso J., Gadsboll N., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation // Arch Intern Med. – 2010. – Vol. 170. – P. 1433–1441.
13. Ho K.K., Pinsky J.L., Kannel W.B., Levy D. The epidemiology of heart failure: the Framingham Study // J Am CollCardiol. – 1993. – Vol. 22. – P. 6A-13A.
14. James S.K., Roe M.T., Cannon C.P., Cornel J.H., Horrow J., Husted S., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised Platelet inhibition and patient Outcomes (PLATO) trial. – BMJ. – 2011. – Vol. 342. – P. d3527.
15. Lane D.A., Lip G.Y.H. Use of the CHA2DS2-VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation // Circulation. – 2012. – Vol. 126. – P. 860–865.
16. Roldan V., Marin F., Manzano-Fernandez S., Gallego P., Vilchez J.A., Valdes M., et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation // J Am Coll Cardiol. – 2013. – Vol. 62. – P. 2199–2204.
17. Savarese G., Giugliano R.P., Rosano G.M., McMurray J., Magnani G., Filippatos G., et al. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis // JACC Heart Fail. – 2016. – Vol. 4 (11). – P. 870–880.
18. Sharma M., Cornelius V.R., Patel J.P., Davies J.G., Molokhia M. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis // Circulation. – 2015. – Vol. 132 (3). – P. 194–204.
19. Valgimigli M., Bueno H., Byrne R.A., Collet J.-P., Costa F., Jeppsson A. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) // European Heart Journal. – 2018. – Vol. 39, Is. 3. – P. 213–260.
20. Van Walraven C., Hart R.G., Connolly S., Austin P.C., Mant J., Hobbs F.D., et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the Atrial Fibrillation Investigators // Stroke. – 2009. – Vol. 40. – P. 1410–1416.
21. Zannad F., Stough W.G., Regnault V., Gheorghiade M., Deliargyris E., Gibson C.M. et al. Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges // Int J Cardiol. – 2013. – Vol. 67. – P. 1772–1782.
How to Cite